# A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke

Study · id `cardio:ct-nct07754825` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07754825](<https://clinicaltrials.gov/study/NCT07754825>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07754825

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT07754825. Randomized; double masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT07754825, source copy `cardio:ctgov-nct07754825-2026-10-19`, retrieved 2026-10-26)
- Planned start: 2026-12-01 (anticipated) (ClinicalTrials.gov record NCT07754825, source copy `cardio:ctgov-nct07754825-2026-10-19`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07754825, source copy `cardio:ctgov-nct07754825-2026-10-19`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07754825, source copy `cardio:ctgov-nct07754825-2026-10-19`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07754825, source copy `cardio:ctgov-nct07754825-2026-10-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07754825-2026-10-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke
- Condition: Acute Ischemic Stroke
- Intervention (Drug): LT3001 Drug:high dose
- Intervention (Drug): LT3001 Drug: low dose
- Intervention (Drug): Placebo
- Lead sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Shanghai Pharmaceuticals Holding Co., Ltd (`cardio:org-shanghai-pharmaceuticals-holding-co-ltd`)

## Provenance

Content hash: 97981eb52a1ec1e83daf5a6659a9b9d1bb04a9bafec33ada8b081eec72131988
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
